Drawing from reports indicating that the up-regulation of AXL kinase and its ligand GAS6 can confer resistance to EGFR-targeted therapy in lung cancer [21,22], we investigated the expression levels of these genes in both lung and melanoma persister cells. The gene discussed is GAS6; the disease is melanoma.